CN105992591A - 用于降低抗原特异性免疫原性的组合物和方法 - Google Patents

用于降低抗原特异性免疫原性的组合物和方法 Download PDF

Info

Publication number
CN105992591A
CN105992591A CN201480062068.0A CN201480062068A CN105992591A CN 105992591 A CN105992591 A CN 105992591A CN 201480062068 A CN201480062068 A CN 201480062068A CN 105992591 A CN105992591 A CN 105992591A
Authority
CN
China
Prior art keywords
opls
antigen
composition
fviii
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480062068.0A
Other languages
English (en)
Chinese (zh)
Inventor
塞茜·巴鲁-莱尔
马修·P.·科斯洛斯基
克里希卡·阿伦·谢蒂
詹妮弗·李·施耐德
阿纳斯·法萨拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Publication of CN105992591A publication Critical patent/CN105992591A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C07F9/106—Adducts, complexes, salts of phosphatides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480062068.0A 2013-09-24 2014-09-24 用于降低抗原特异性免疫原性的组合物和方法 Pending CN105992591A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361881857P 2013-09-24 2013-09-24
US61/881,857 2013-09-24
PCT/US2014/057234 WO2015048145A1 (en) 2013-09-24 2014-09-24 Compositions and methods for reducing antigen-specific immunogenicity

Publications (1)

Publication Number Publication Date
CN105992591A true CN105992591A (zh) 2016-10-05

Family

ID=52744422

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480062068.0A Pending CN105992591A (zh) 2013-09-24 2014-09-24 用于降低抗原特异性免疫原性的组合物和方法

Country Status (6)

Country Link
US (1) US20160243220A1 (https=)
EP (1) EP3049103B1 (https=)
JP (1) JP6783652B2 (https=)
CN (1) CN105992591A (https=)
ES (1) ES2807550T3 (https=)
WO (1) WO2015048145A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4304643A1 (en) * 2021-03-11 2024-01-17 Lapix Therapeutics, Inc. Compositions and methods for reducing immune intolerance
JP7804370B2 (ja) 2021-08-13 2026-01-22 ラピックス セラピューティクス， インコーポレイテッド 免疫不寛容を軽減し、自己免疫障害を治療するための組成物及び方法
JP2024532810A (ja) * 2021-08-13 2024-09-10 ラピックス セラピューティクス， インコーポレイテッド 免疫不寛容を軽減し、自己免疫障害を治療するための組成物及び方法
EP4608969A1 (en) 2022-10-25 2025-09-03 Lapix Therapeutics, Inc. Immune cell-engrafted non-human animals and non-human animal models
WO2024118602A1 (en) 2022-11-29 2024-06-06 Lapix Therapeutics, Inc. Compositions and methods for reducing immune intolerance and treating autoimmune disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625584B2 (en) 2000-11-30 2009-12-01 The Research Foundation Of State University Of New York Method of complexing a protein by the use of a dispersed system and proteins thereof
US8110218B2 (en) 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
US7351688B2 (en) * 2003-02-05 2008-04-01 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein formulations
WO2007117469A2 (en) * 2006-03-30 2007-10-18 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
US7875288B2 (en) 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Method for treating blood coagulation disorders
EP3058953A1 (en) * 2009-07-07 2016-08-24 The Research Foundation Of State University Of New York Lipidic compositions for induction of immune tolerance

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VIVEK S.PUROHIT ET AL.: "Lower Inhibitor Development in Hemophilia A Mice following Administration of Recombinant Factor VIII-O-Phospho-L-serine Complex*", 《THE JOURNALOF BIOLOGICAL CHEMISTRY》 *

Also Published As

Publication number Publication date
JP2016531853A (ja) 2016-10-13
EP3049103A4 (en) 2017-09-27
WO2015048145A1 (en) 2015-04-02
ES2807550T3 (es) 2021-02-23
US20160243220A1 (en) 2016-08-25
JP6783652B2 (ja) 2020-11-11
WO2015048145A9 (en) 2015-06-25
EP3049103B1 (en) 2020-06-24
EP3049103A1 (en) 2016-08-03

Similar Documents

Publication Publication Date Title
US20250319075A1 (en) Phosphoserine containing compositions for immune tolerance induction
Cruz-Leal et al. The vacuolar pathway in macrophages plays a major role in antigen cross-presentation induced by the pore-forming protein sticholysin II encapsulated into liposomes
US20160060324A1 (en) Methods and Compositions for Treating Bleeding Disorders
WO2011005850A1 (en) Lipidic compositions for induction of immune tolerance
EP3049103B1 (en) Compositions and methods for reducing antigen-specific immunogenicity
Glassman et al. Phosphatidylserine is not just a cleanup crew but also a well-meaning teacher
US20210147544A1 (en) Methods and compositions for targeted delivery of active agents and immunomodulatory agents to lymph nodes
JP2017036299A (ja) ミエリン塩基性タンパク質のオリゴペプチドフラグメントを含有するリポソーム、医薬組成物および多発性硬化症の治療方法
US11701328B2 (en) Phosphoserine containing compositions for immune tolerance induction
US10064922B2 (en) Compositions and methods for immune tolerance induction
JP6014241B2 (ja) ミエリン塩基性タンパク質のオリゴペプチドフラグメントを含有するリポソーム、医薬組成物および多発性硬化症の治療方法
US20220016241A1 (en) Compositions and methods for reducing antigen-specific immunogenicity
US20230381309A1 (en) Methods of treating diffuse large b-cell lymphoma
van Veelen et al. Anionic 1, 2ͲDistearoylͲsnͲglyceroͲ3Ͳ phosphoglycerol (DSpG) liposomes induce anƟgenͲspecific regulatory T cells and prevent atherosclerosis in mice
Glassman Phosphatidylserine-based Nanoparticles for Tolerance Induction Towards Therapeutic Proteins

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20161005

RJ01 Rejection of invention patent application after publication